We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Molecular Diagnostic Test for Congenital Syphilis Could Enable Immediate Treatment

By LabMedica International staff writers
Posted on 15 Sep 2023

Newborns with congenital syphilis may suffer from issues like bone damage, severe anemia, enlarged liver and spleen, jaundice, nerve issues leading to blindness or hearing loss, meningitis, or skin conditions. More...

The severity of these health issues in the baby largely depends on whether the mother has received timely treatment for syphilis. At present, there are no sensitive diagnostic tests to confirm if a newborn has congenital syphilis. The current diagnostic approach is based on whether the mother has been treated for syphilis or if the baby shows any symptoms of the disease, along with abnormally high syphilis serology labs. As a result, doctors are forced to go through a checklist to assess if the mother has the infection and monitor the newborn for months to establish their infection status. Now, a molecular diagnostic test being developed for the detection of congenital syphilis could enable physicians to begin immediate treatment for newborns.

Researchers from UTHealth Houston (Houston, TX, USA) are working on creating a molecular diagnostic test that can quickly identify congenital syphilis, enabling immediate treatment for the affected newborns. The team is also planning a multicenter study that will examine the neurodevelopmental outcomes in babies born with the disease. This is particularly important as 60% of untreated babies born with syphilis suffer from neurodevelopmental issues.

“Our goal is to create a test for syphilis that is effective, so we can do immediate treatment,” said Irene Stafford, MD, at UTHealth Houston who is the principal investigator. “This test could be an incredible step in treating and diagnosing congenital syphilis.”

Related Links:
UTHealth Houston 


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.